12th October 2022
Professor Fran Balkwill from Barts Cancer Institute at Queen Mary University of London has received a UK Research and Innovation (UKRI) Frontier Research grant of over £2 million to investigate the most effective ways to remodel cancers to enhance the effects of immunotherapy.
Read more14th March 2022
Dr Michelle Lockley from Barts Cancer Institute at Queen Mary University of London has received funding from Barts Charity and the Anticancer Fund to investigate a new personalised treatment approach for ovarian cancer that has returned after previous chemotherapy.
Read more25th October 2021
A research project led by Professor Fran Balkwill from Barts Cancer Institute at Queen Mary University of London features in a world-first free exhibition exploring the revolution in science that is transforming cancer care.
Read more15th June 2021
Researchers from Barts Cancer Institute at Queen Mary University of London, led by Professor Fran Balkwill and Dr Oliver Pearce, have built two 3D multi-cellular models of the human tumour microenvironment (TME) in ovarian cancer. The models, which are the first created from the CanBuild project, have revealed novel insights into the role of the TME in cancer progression.
Read more13th May 2021
A large-scale randomised trial of annual screening for ovarian cancer did not succeed in reducing deaths from the disease, despite one of the screening methods tested detecting cancers earlier, according to results published in The Lancet.
Read more10th April 2021
Research from Barts Cancer Institute, Queen Mary University of London, has revealed novel insights into the effects of chemotherapy on the tumour microenvironment (TME). The study found that chemotherapy enhances the anti-tumour actions of immune cells within the TME and their ability to support immune responses against cancer.
Read more